Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring, Other Apr 04 | 2024Ascletis MASH Development Updates; Biolinq Raises $58M for Intradermal Glucose Sensor; Arrowhead Initiates Ph3 Plozasiran TrialsPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, SGLT2i Apr 03 | 2024Clive Meanwell and Ian Reed Take on the Obesity Market; Novo Initiates Icodec Switching Trial; Mounjaro Faces Continued US Supply Constraints; Amarin’s Vazkepa Exclusivity ExtendedPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Apr 02 | 2024Biomea and Fractyl Q4 ’23 Earnings; Glucotrack Implantable CGM Update; Costco Weight Loss Program; D&D Fast Track Designation in MASH; New Aligos Ph2a MASH Trial; Sernova Cell Pouch UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Other Apr 01 | 2024Zepbound Supply Constraints Observed; NeuroBo Completes Ph2a MASH Trial Enrollment; Galectin Q4 ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Mar 28 | 2024FDA Approves Akebia’s Vadadustat; Inventiva and NeuroBo Q4 ’23 Earnings; Supersapiens to Relaunch in US; Sagimet MASH Development UpdatesPurchase Blast
$599
Posted in: GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, Other Mar 27 | 2024Altimmune Q4 ’23 Earnings Update; Lilly Insulin Supply Shortage; 89bio Receives EMA PRIME Designation for MASH; Ypsomed Sells Needle and BGM Business; Thomas Danne Joins JDRFPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring Mar 26 | 2024Viking’s Momentum Continues with Ph1 Oral Obesity Win; Dexcom Faces Minor Setback in Abbott LitigationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other Mar 25 | 2024Novo acquires Cardior Pharmaceuticals; Novo initiates Ph2 Dual Agonist Trials in T2DM and Obesity; Esperion CLEAR Outcomes Investor CallPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Mar 22 | 2024Novo Initiates Additional Ph3 Cagrisema T2DM Trials; CLEAR Outcomes Approved by FDA and Received Positive CHMP OpinionPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Mar 21 | 2024Wegovy SELECT Label Analysis; CMS Opens Obesity CoveragePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Mar 21 | 2024Awiqli (QW Insulin Icodec) Receives Positive CHMP Opinion; Oprah TV Special Spotlights Zepbound and WegovyPurchase Blast
$599
Posted in: Other, SGLT2i Mar 19 | 2024Inventiva Interim Ph2a MASH Results; Madrigal Announces $600M Public Offering; 89bio Initiates Ph3 ENLIGHTEN-Fibrosis MASH TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Mar 18 | 2024Icodec up for CHMP Opinion; March CHMP Agenda; Galmed Granted MASH Combo Patent; Sequel’s twiist AID Receives 510(k) ClearancePurchase Blast
$599
Posted in: GLP-1RA, Other Mar 15 | 2024Rezdiffra Patient and HCP Websites Observed; Terns Q4 ‘23 EarningsPurchase Blast
$599
Posted in: Other Mar 14 | 2024Madrigal’s Resmetirom Approved as First Treatment for MASHPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, SGLT2i Mar 14 | 2024CBO Hints at Medicare Coverage for Obesity Drugs; AZ Initiates Ph3 Balcinrenone/Dapa TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Mar 13 | 2024Ionis Ph2 MASH Results; New BI Ph3 Survodutide MASH Trial; Silence Ph2 Lp(a) Results; Lilly Partners with Amazon Pharmacy; Arecor Partners for Oral GLP-1RA; Ascensia Expands PSPPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Mar 12 | 2024Lexicon Sota T1DM Indication and CKM; Lilly Expands Redwire Collaboration; 89bio Initiates Ph3 ENLIGHTEN MASH Program; Fractyl Reports Preclinical Rejuva Findings; Welldoc Receives CE Mark for BluestarPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Mar 11 | 2024Lexicon Q4 ’23 Earnings; Lexicon to Resubmit Sota T1DM NDA; MannKind INHALE-3 Initial Results; Praluent Receives Pediatric HeFH FDA ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Mar 09 | 2024ATTD 2024 Key Press Releases Day 4 (March 9)Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
